Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT ID: NCT06776432
Last Updated: 2025-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2025-04-02
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Effects of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea
NCT06283017
StimAire Sleep Study
NCT05374941
Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea
NCT03892772
Pivotal Study of the iNAP® in Adults With OSA
NCT03544463
Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
NCT04611750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A: Sivopixant
Participants will receive sivopixant oral tablets once daily at bedtime for 17 days.
Sivopixant
Administered as specified in the treatment arm
Placebo
Participants will receive placebo to match the study drug during the 17 days of Part A followed by 13 days of Part B.
Placebo
Administered as specified in the treatment arm.
Part B I: Acetazolamide
After completing Part A, participants will receive acetazolamide oral tablets once daily at bedtime for 3 days.
Acetazolamide
Administered as specified in the treatment arm
Part B II: SASS-001
After completing Part B I, participants will receive SASS-001 oral tablets once daily at bedtime for 10 days.
SASS-001
Administered as specified in the treatment arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sivopixant
Administered as specified in the treatment arm
Placebo
Administered as specified in the treatment arm.
Acetazolamide
Administered as specified in the treatment arm
SASS-001
Administered as specified in the treatment arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable heart failure with reduced ejection fraction (NYHA class 1-3 inclusive) with or without atrial fibrillation
* Heart failure with preserved ejection fraction (NYHA class 1-3 inclusive) and hypertension (BP\>120/80 mmHg at screening visit despite the treatment with ≥2 antihypertensives) with or without atrial fibrillation
* Persistent atrial fibrillation (continuous and sustained for more than 7 days, rate controlled with resting HR\<100bpm)1 without heart failure
* History of primary (essential) hypertension with BP at screening visit \>130/80 mmHg despite the treatment with \>2 antihypertensives
* Evidence of complex sleep apnea (CPAP-emergent central sleep apnea with documented CAI\>5 events/h on CPAP within 1 year from screening)
Standard care for heart failure and atrial fibrillation for at least 3 weeks before the screening visit
OSA measures Average ODI4 between 7 and 55 events/h, inclusive, and average SpO2 ≥88% from continuous home pulse oximetry recordings at screening.
AHI4 (Hypopneas defined by 4% oxygen desaturation) of \>10 to ≤60 events/h
1. At minimum of 25% central or mixed apneas (as proportion of total apneas) with a minimum of 2.5 central or mixed apneas/hour of sleep
2. OR evidence of clear Cheyne-Stokes breathing pattern during the baseline PSG (regardless of central apnea component).
3. OR evidence of OSA with LGn \>0.5 at the baseline PSG (regardless of central apnea component) Average SpO2 during sleep ≥88%
Weight BMI between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive
Male participants If male and sexually active with female partner(s) of childbearing potential, participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified contraception. Male participants must refrain from donating sperm for the duration of the study and for 3 months after the last dose of study treatment.
Female participants If a woman of childbearing potential (WOCBP), the participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified contraception. All WOCBP must have negative result of a serum pregnancy test performed at screening.
If female and of non-childbearing potential, the participant must be either postmenopausal or permanently sterile (e.g. bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
Informed Consent Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the Screening Visit procedures.
Participant must be able to understand the nature of the study and must have the opportunity to have any questions answered.
Patients currently using PAP will be eligible for inclusion in the study if they express willingness to discontinue treatment for a minimum of 7 days before baseline SpO2 assessments, until the study completion.
Exclusion Criteria
Dyspnea at rest or patients with heart failure class IV NYHA
Blood pressure \<90/50 mmHg or \>160/100 mmHg at V1.
Medical Conditions Recent (\<3 months) episode of acute myocardial infarction or acute decompensated heart failure.
History of stroke.
History of sustained ventricular tachyarrhythmias or other severe arrhythmias without defibrillator implanted.
Heart failure primarily caused by valvular, post-partum cardiomyopathy or active myocarditis
History of obesity-hypoventilation syndrome or respiratory disturbance due to opioids.
History of bronchiectasis and uncontrolled asthma.
History of severe chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \<50% of predicted (European Respiratory Society criteria)
Started treatment with β-blockers \<3 months before screening. Patients not taking β-blockers or taking β-blockers for \>3 months can be enrolled.
Narcolepsy, restless leg syndrome requiring medication, REM sleep behavior disorder.
Pronounced anatomical abnormalities of upper airway (adenoid vegetations, grade ≥3 tonsillar hypertrophy, etc.), pronounced micrognathia, or pronounced incomplete development of the lower jaw.
History of schizophrenia, schizoaffective disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) or International Classification of Disease tenth edition criteria.
Medically unexplained positive screen for drugs of abuse (excluding THC/marijuana) or history of substance use disorder as defined in DSM-V within 24 months prior to Screening Visit.
A significant illness or infection requiring medical treatment in the past 30 days as determined by investigator.
Clinically significant cognitive dysfunction as determined by investigator.
Women who are pregnant or nursing.
History of kidney stones
Prior/Concomitant Therapy Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 1 week before the baseline SpO2 assessments and are not used during participation in the study (through V7). Patients that are non-compliant to CPAP (less than 4hr/night for 5 days/week) can be enrolled, as well as patients who are naïve to PAP and patients who discontinued PAP previously. PAP compliant patients cannot be enrolled.
History of chronic oxygen therapy.
Concomitant use of medications from the list of disallowed medications.
Prior/Concurrent Clinical Study Experience Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
Diagnostic Assessments Hepatic cirrhosis, hepatictransaminases \> 2X the upper limit of normal (ULN), total bilirubin \>1.5X ULN (unless confirmed Gilbert syndrome), estimated glomerular filtration rate \< 40 ml/min.
Participants with reduced sodium and/or potassium blood serum levels.
Participants with suprarenal gland failure.
Participants with hyperchloremic acidosis.
Other Exclusions:
Night- or shift-work sleep schedule which causes the major sleep period to be during the day.
Employment as a commercial driver or operator of heavy or hazardous equipment.
Typically smoking more than 10 cigarettes or 2 cigars per day, or inability to abstain from smoking during overnight PSG visits.
Unwilling to use specified contraception.
History of regular alcohol consumption of more than 14 standard units per week (males) or more than 7 standard units per week (females), or unwillingness to limit alcohol consumption to no greater than 2 units/day (males), 1 unit per day (females). Alcohol is not to be consumed within 3 hours of bedtime or on PSG nights.
Unwilling to agree to limit during the study period caffeinated beverage intake (e.g., coffee, cola, tea) to 400 mg/day or less of caffeine, not to be used within 3 hours of bedtime.
Any condition that in the investigator's opinion would present an unreasonable risk to the participant, including recent (\<1 year) motor vehicle accident due to drowsy driving, or which would interfere with their participation in the study or confound study interpretation.
Participant considered by the investigator, for any reason, an unsuitable candidate to receive sivopixant or acetazolamide or unable or unlikely to understand or comply with the dosing schedule or study evaluations.
Allergy to study drugs
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shionogi Apnimed Sleep Science
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chief Scientific Officer
Role: STUDY_DIRECTOR
Shionogi Apnimed Sleep Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California, United States
Teradan Clinical Trials
Brandon, Florida, United States
PharmaDev Clinical Research Institute, LLC
Miami, Florida, United States
Infinity Medical Research
North Dartmouth, Massachusetts, United States
John D. Dingell VA Medical Center
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Intrepid Research, LLC
Cincinnati, Ohio, United States
OnSite Clinical Solutions
Rock Hill, South Carolina, United States
Huntsville Research Institute LLC
Huntsville, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SVA-SAS-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.